Barclays analyst Gena Wang notes that Merck (MRK) and AstraZeneca (AZN) reported Q2 earnings, which the firm sees as neutral to Moderna (MRNA) and negative to Ionis Pharmaceuticals (IONS). Regarding Merck’s update, the firm notes enflonsia launch is underway and Merck/Moderna’s INT oncology partnership continues to advance, both events seen as neutral by Barclays to Moderna. Regarding AstraZeneca’s update, the firm believes the company’s Wainua Q2 revenue miss is a negative to Ionis. Q2 sales were $44M, missing Bloomberg consensus of $53M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: